Diplopia

A 48-year-old man presented to the Lahey Eye Clinic as a new patient for care after recent head trauma while he was in another state.

A phase 3 clinical trial of veligrotug, an anti-insulin-like growth factor-1 receptor antibody, met primary and secondary endpoints involving proptosis, clinical activity scores and diplopia for the treatment of chronic thyroid eye disease.

Viridian Therapeutics reported positive topline data from the phase 3 THRIVE clinical trial of veligrotug for the treatment of active thyroid eye disease.

It’s impossible to encapsulate all the incredible advice I’ve received from professional mentors throughout the years, but here is a partial list of some memorable and impactful moments.

Diplopia should raise clinician suspicion for giant cell arteritis when associated with cephalic symptoms and prompt the use of corticosteroids to prevent ocular ischemic complications, according to researchers.

A 37-year-old white woman 2 weeks postpartum from an uncomplicated pregnancy and normal spontaneous vaginal delivery presented to the Tufts Medical Center emergency room.

Modern glaucoma care is all about the patient, according to a speaker at the American Glaucoma Society meeting.

A 42-year-old man with no significant medical history presented initially in the emergency department of an outside hospital with a 2-week history of progressive bilateral nasal congestion, facial pain and pressure.

Adults with long-standing thyroid eye disease and low clinical activity scores had greater reductions in proptosis with teprotumumab compared with placebo, according to data published in The Journal of Clinical Endocrinology & Metabolism.

A 90-year-old woman was referred by her ophthalmologist to the emergency department at our institution following several weeks of discomfort and a “pinching” sensation in the left eye.